VCA Antech, Director of Clinical Studies for Mars Veterinary Health
Dr. Philip J. Bergman is the Director of Clinical Studies for Mars Veterinary Health and VCA and serves as the principal veterinary investigator for the fully licensed canine melanoma vaccine, Oncept®. He is also an adjunct faculty member at the Memorial Sloan-Kettering Cancer Center. Before joining VCA-Antech, Dr. Bergman was the Chief Medical Officer at BrightHeart Veterinary Centers from July 2007 to August 2011, and he led the Donaldson-Atwood Cancer Center at AMC from 1999 to 2007. After finishing veterinary school at Colorado State University (CSU) in 1990, he interned at Kansas State university (1990-1991) and returned to CSU for his medical oncology residency (1991-1994). He then earned a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (1994-1999). Dr. Bergman has also served as Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society.
Dr. Philip J. Bergman is the Director of Clinical Studies for Mars Veterinary Health and VCA and serves as the principal veterinary investigator for the fully licensed canine melanoma vaccine, Oncept®. He is also an adjunct faculty member at the Memorial Sloan-Kettering Cancer Center. Before joining VCA-Antech, Dr. Bergman was the Chief Medical Officer at BrightHeart Veterinary Centers from July 2007 to August 2011, and he led the Donaldson-Atwood Cancer Center at AMC from 1999 to 2007. After finishing veterinary school at Colorado State University (CSU) in 1990, he interned at Kansas State university (1990-1991) and returned to CSU for his medical oncology residency (1991-1994). He then earned a PhD Fellowship in human cancer biology from the M.D. Anderson Cancer Center in Houston (1994-1999). Dr. Bergman has also served as Chair of the ACVIM Board of Regents and President of the Veterinary Cancer Society.
